The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Celgene; Merck; SERVIER; Shire
Research Funding - AstraZeneca; Celgene; Halozyme; Merck; Novartis; Pfizer; Roche; SERVIER

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
 
Quisette Janssen
No Relationships to Disclose
 
Jacob L. van Dam
No Relationships to Disclose
 
Marc G.H. Besselink
No Relationships to Disclose
 
Marjolein Y.V. Homs
No Relationships to Disclose
 
Geertjan van Tienhoven
No Relationships to Disclose
 
Johanna W. Wilmink
No Relationships to Disclose
 
Bas Groot Koerkamp
No Relationships to Disclose